ID
SRPT icon

Integral Derivatives’s Sarepta Therapeutics SRPT Stock Holding History

Integral Derivatives’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-14,622
Closed -$373K – 1559
2013
Q4 		$298K Buy
+14,622
New +$434K ﹤0.01% 1216

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Integral Derivatives's SRPT Position: Q1 2014 in Review

Integral Derivatives sold out of Sarepta Therapeutics (SRPT) in Q1 2014, closing a stake of 14,622 shares — an estimated $373K sold.

Integral Derivatives first reported a position in SRPT in Q4 2013 and held it in 1 quarter. The position peaked at $298K in Q4 2013. 114 funds tracked by Wall St. Rank hold SRPT as of Q1 2014.

  • Integral Derivatives reported no remaining Sarepta Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Integral Derivatives sold 14,622 Sarepta Therapeutics shares in Q1 2014, an estimated $373K.
  • Integral Derivatives first reported a position in Sarepta Therapeutics in Q4 2013 and held it in 1 quarter.
  • Integral Derivatives's Sarepta Therapeutics position peaked at $298K in Q4 2013.
  • 114 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2014.

Based on Integral Derivatives's 13F filing for Q1 2014, filed 2 May 2014.